Clinical evaluation of INNO-LiPA HPV Genotyping EXTRA II assay using the VALGENT framework

Xu, Lan (avtor), Padalko, Elizaveta (avtor), Oštrbenk Valenčak, Anja (avtor), Poljak, Mario (avtor), Arbyn, Marc (avtor)

In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping performance of the INNO-LiPA HPV Genotyping Extra II (INNO-LiPA) within the VALGENT-3 framework. VALGENT is designed to assess the analytical and clinical performance of HPV tests with genotyping capacity. The VALGENT-3 panel comprised 1300 consecutive cervical cell specimens enriched with 300 samples with abnormal cytology obtained from women attending the Slovenian cervical cancer screening programme. The INNO-LiPA allows type-specific detection of 32 HPV types; however, for the clinical accuracy assessment, we considered it as high-risk (hr)HPV positive when at least one of the following HPV types was present: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and HPV68. Clinical accuracy for detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) was compared between INNO-LiPA and Hybrid Capture 2 (HC2), which is a standard comparator test for HPV tests used in cervical cancer screening. In addition, hrHPV and type-specific detection HPV types were compared between INNO-LiPA and Linear Array HPV Genotyping Test (Linear Array). The prevalence of hrHPV determined by INNO-LiPA was 17.1% (95% CI, 15.0–19.2%) in the screening population. HrHPV testing with INNO-LiPA had a sensitivity for CIN2+ of 96.9% (95% CI, 92.1–99.1%) which was non-inferior to HC2 (relative sensitivity of 1.01; 95% CI, 0.97–1.04; p$_{n.inf}$ = 0.0002) and a specificity for ≤CIN1 of 85.3% (95% CI, 83.2–87.3%) which was inferior to HC2 (relative specificity of 0.95; 95% CI, 0.93–0.97; p$_{n.inf}$ = 0.9998). Genotyping agreement between INNO-LiPA and Linear Array was excellent for hrHPV, HPV16, HPV18, HPV35, HPV45, HPV58 and HPV59, but good or fair for other HPV types. To conclude, INNO-LiPA demonstrated non-inferior clinical sensitivity but lower specificity compared to HC2 in addition to excellent concordance compared to Linear Array for hrHPV and some genotypes.

• Jezik: Angleški jezik
• Ključne besede: INNO-LiPA, VALGENT, HPV genotyping, cervical cancer, human papillomavirus, clinical validation, Hybrid Capture 2, Linear Array, HPV, INNO - LiPA HPV genotyping EXTRA II
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2018
• Št. strani: 11 str.
• Številčenje: Vol. 19, iss. 9, art. 2704
• PID: 20.500.12556/RUL-131628
• ISSN pri članku: 1422-0067
• DOI: 10.3390/ijms19092704
• COBISS.SI-ID: 129639683
• Datum objave v RUL: 30.09.2021

XU, Lan, PADALKO, Elizaveta, OŠTRBENK VALENČAK, Anja, POLJAK, Mario in ARBYN, Marc, 2018, Clinical evaluation of INNO-LiPA HPV Genotyping EXTRA II assay using the VALGENT framework. International journal of molecular sciences [na spletu]. 2018. Vol. 19, no. 9,  2704. [Dostopano 26 marec 2025]. DOI 10.3390/ijms19092704. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=131628

Gradivo je del revije

• Naslov: International journal of molecular sciences
• Skrajšan naslov: Int. j. mol. sci.
• Založnik: MDPI
• ISSN: 1422-0067
• COBISS.SI-ID: 2779162

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 11.09.2018

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: humani papiloma virus, HPV genotipizacija, rak materničnega vratu

Projekti

• Financer: EC - European Commission
• Program financ.: FP7
• Številka projekta: 603019
• Naslov: Comparing health services interventions for the prevention of HPV-related cancer
• Akronim: COHEAHR